With nominations currently open for the 10th Global Generics & Biosimilars Awards 2023 – which will take place on Wednesday 25 October at the Hotel Porta Fira in Barcelona (Also see "GGB Awards Returns To Barcelona In Its 10th Year" - Generics Bulletin, 23 February, 2023.) – Generics Bulletin’s editors discuss details of the event in this podcast, including details of our 14 categories and tips on how to make your entries stand out.
Podcast: The Global Generics & Biosimilars Awards 2023
We Discuss Awards Categories, Entry Tips, And Other Details Of The Event
With entries currently open for the Global Generics & Biosimilars Awards 2023 – which will take place on Wednesday 25 October at the Hotel Porta Fira in Barcelona – we talk through the categories that companies can enter, tips to make entries stand out, as well as the benefits of entering and attending the awards.
More from Generics
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.
• By
A UK High Court justice came down on the side of Glenmark in AstraZeneca’s bid to enjoin the firm from launching a generic version of its Forxiga blockbuster before judgment is delivered in the firms’ patent-litigation clash.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
More from Products
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.